TY - JOUR
T1 - Impact of psm-mec in the mobile genetic element on the clinical characteristics and outcome of SCCmec-II methicillin-resistant Staphylococcus aureus bacteraemia in Japan
AU - Aoyagi, Tetsuji
AU - Kaito, C.
AU - Sekimizu, K.
AU - Omae, Y.
AU - Saito, Y.
AU - Mao, H.
AU - Inomata, S.
AU - Hatta, M.
AU - Endo, S.
AU - Kanamori, H.
AU - Gu, Y.
AU - Tokuda, K.
AU - Yano, H.
AU - Kitagawa, M.
AU - Kaku, M.
N1 - Funding Information:
The authors thank Makoto Katsumi, Mina Kawauchi and Mitsuaki Nagasawa for their technical assistance. This study was supported by Grants-in-Aid for Scientific Research (23249009, 24590519).
Publisher Copyright:
© 2014 The Authors.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - Over-expression of alpha-phenol-soluble modulins (PSMs) results in high virulence of community-associated methicillin-resistant Staphylococcus aureus (MRSA). The psm-mec gene, located in the mobile genetic element SCCmec-II, suppresses PSMαs production. Fifty-two patients with MRSA bacteraemia were enrolled. MRSA isolates were evaluated with regard to the psm-mec gene sequence, bacterial virulence, and the minimum inhibitory concentration (MIC) of vancomycin and teicoplanin. Fifty-one MRSA isolates were classified as SCCmec-II, and 10 had one point mutation in the psm-mec promoter. We compared clinical characteristics and outcomes between mutant MRSA and wild-type MRSA. Production of PSMα3 in mutant MRSA was significantly increased, but biofilm formation was suppressed. Wild-type MRSA caused more catheter-related bloodstream infections (30/41 vs. 3/10, p 0.0028), whereas mutant MRSA formed more deep abscesses (4/10 vs. 3/41, p 0.035). Bacteraemia caused by mutant MRSA was associated with reduced 30-day mortality (1/10 vs. 13/41, p 0.25), although this difference was not significant. The MIC90 of teicoplanin was higher for wild-type MRSA (1.5 mg/L vs. 1 mg/L), but the MIC of vancomycin was not different between the two groups. The 30-day mortality of MRSA with a high MIC of teicoplanin (≥1.5 mg/L) was higher than that of strains with a lower MIC (≤0.75 mg/L) (6/10 vs. 6/33, p 0.017). Mutation of the psm-mec promoter contributes to virulence of SCCmec-II MRSA, and the product of psm-mec may determine the clinical characteristics of bacteraemia caused by SCCmec-II MRSA, but it does not affect mortality.
AB - Over-expression of alpha-phenol-soluble modulins (PSMs) results in high virulence of community-associated methicillin-resistant Staphylococcus aureus (MRSA). The psm-mec gene, located in the mobile genetic element SCCmec-II, suppresses PSMαs production. Fifty-two patients with MRSA bacteraemia were enrolled. MRSA isolates were evaluated with regard to the psm-mec gene sequence, bacterial virulence, and the minimum inhibitory concentration (MIC) of vancomycin and teicoplanin. Fifty-one MRSA isolates were classified as SCCmec-II, and 10 had one point mutation in the psm-mec promoter. We compared clinical characteristics and outcomes between mutant MRSA and wild-type MRSA. Production of PSMα3 in mutant MRSA was significantly increased, but biofilm formation was suppressed. Wild-type MRSA caused more catheter-related bloodstream infections (30/41 vs. 3/10, p 0.0028), whereas mutant MRSA formed more deep abscesses (4/10 vs. 3/41, p 0.035). Bacteraemia caused by mutant MRSA was associated with reduced 30-day mortality (1/10 vs. 13/41, p 0.25), although this difference was not significant. The MIC90 of teicoplanin was higher for wild-type MRSA (1.5 mg/L vs. 1 mg/L), but the MIC of vancomycin was not different between the two groups. The 30-day mortality of MRSA with a high MIC of teicoplanin (≥1.5 mg/L) was higher than that of strains with a lower MIC (≤0.75 mg/L) (6/10 vs. 6/33, p 0.017). Mutation of the psm-mec promoter contributes to virulence of SCCmec-II MRSA, and the product of psm-mec may determine the clinical characteristics of bacteraemia caused by SCCmec-II MRSA, but it does not affect mortality.
KW - Clinical characteristics
KW - MRSA
KW - Phenol-soluble modulins
KW - Teicoplanin
KW - Vancomycin
KW - psm-mec mutation
UR - http://www.scopus.com/inward/record.url?scp=84908030409&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908030409&partnerID=8YFLogxK
U2 - 10.1111/1469-0691.12575
DO - 10.1111/1469-0691.12575
M3 - Article
C2 - 24476401
AN - SCOPUS:84908030409
SN - 1198-743X
VL - 20
SP - 912
EP - 919
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
IS - 9
ER -